Novartis AG
COMBINATION THERAPIES OF EGFRVIII CHIMERIC ANTIGEN RECEPTORS AND PD-1 INHIBITORS

Abstract:

Provided are compositions and methods for treating diseases, e.g., cancers, e.g., diseases associated with expression of an antigen, e.g., EGFRvIII, comprising administering a cell that expresses a chimeric antigen receptor (CAR) specific to the antigen, e.g., EGFRvIII, in combination with a PD-1 inhibitor.